Shanghai Pharmaceuticals Holding Co., Ltd. (SPH) released its 2025 Sustainability Report, underscoring improved financial results, stronger R&D capabilities and higher ESG ratings.
Revenue and Profitability • Operating revenue rose 3.03 % year-on-year to CNY 283.58 billion. • Net profit attributable to shareholders jumped 25.74 % to CNY 57.25 billion. • Total assets expanded to CNY 233.15 billion, while tax contributions reached CNY 7.70 billion.
ESG Performance • MSCI ESG rating advanced from A to AA, keeping SPH in the global pharmaceutical industry’s leading tier. • Environmental investment totaled about CNY 118 million; 29 subsidiaries now hold ISO 50001 energy-management certification and 24 have been named provincial or national “Green Factories.” • Greenhouse-gas emissions fell to 369,452 tCO₂e, helped by 14.74 million kWh of photovoltaic generation.
Innovation and R&D • R&D spending reached CNY 2.60 billion; 59 new drug projects entered or advanced in clinical stages, including 47 innovative drugs. • SPH’s first-in-class antihypertensive Sitokiren Malate Tablets received marketing approval in December 2025. • The National Key Laboratory of Innovative Immunotherapy became fully operational, focusing on inflammatory and oncology targets.
Product Quality and Supply Chain • No product recalls occurred during the period; 100 % of batches met quality standards. • 128 suppliers hold GMP certification and 392 maintain ISO 9001 quality accreditation. • The company added one new “Green Supply Chain Demonstration Enterprise,” bringing the total to three.
Talent and Safety • The workforce stood at 49,608, with women representing 50.17 %. • Average training hours per employee rose to 39.86; training attendances exceeded 930,000. • No work-related fatalities were reported; safety training coverage reached 100 %.
Community Investment • Public-welfare spending amounted to CNY 16.66 million across 81 projects, while rural-revitalization funding totaled CNY 1.62 million.
Outlook SPH reiterated plans to peak carbon emissions by 2030 for its pharmaceutical units, expand photovoltaic capacity and continue prioritising innovation-driven growth, green operations and supply-chain resilience.
Comments